JP6222779B2 - 心血管治療法 - Google Patents

心血管治療法 Download PDF

Info

Publication number
JP6222779B2
JP6222779B2 JP2014525515A JP2014525515A JP6222779B2 JP 6222779 B2 JP6222779 B2 JP 6222779B2 JP 2014525515 A JP2014525515 A JP 2014525515A JP 2014525515 A JP2014525515 A JP 2014525515A JP 6222779 B2 JP6222779 B2 JP 6222779B2
Authority
JP
Japan
Prior art keywords
signal peptide
peptide fragment
natriuretic signal
type natriuretic
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014525515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524435A (ja
JP2014524435A5 (enExample
Inventor
クリストファー， ジョゼフ ペムバートン，
クリストファー， ジョゼフ ペムバートン，
アーサー， マーク リチャーズ，
アーサー， マーク リチャーズ，
クリストファー， ジョン チャールズ，
クリストファー， ジョン チャールズ，
メイスリ シリワーデナ，
メイスリ シリワーデナ，
Original Assignee
オタゴ イノベーション リミテッド
オタゴ イノベーション リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オタゴ イノベーション リミテッド, オタゴ イノベーション リミテッド filed Critical オタゴ イノベーション リミテッド
Publication of JP2014524435A publication Critical patent/JP2014524435A/ja
Publication of JP2014524435A5 publication Critical patent/JP2014524435A5/ja
Application granted granted Critical
Publication of JP6222779B2 publication Critical patent/JP6222779B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2014525515A 2011-08-18 2012-08-17 心血管治療法 Expired - Fee Related JP6222779B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525140P 2011-08-18 2011-08-18
US61/525,140 2011-08-18
PCT/IB2012/002117 WO2013024362A2 (en) 2011-08-18 2012-08-17 Cardiovascular therapeutics

Publications (3)

Publication Number Publication Date
JP2014524435A JP2014524435A (ja) 2014-09-22
JP2014524435A5 JP2014524435A5 (enExample) 2015-10-01
JP6222779B2 true JP6222779B2 (ja) 2017-11-01

Family

ID=47715527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014525515A Expired - Fee Related JP6222779B2 (ja) 2011-08-18 2012-08-17 心血管治療法

Country Status (8)

Country Link
US (2) US9783574B2 (enExample)
EP (1) EP2744506B1 (enExample)
JP (1) JP6222779B2 (enExample)
CN (1) CN103889438B (enExample)
AU (1) AU2012296266B2 (enExample)
CA (1) CA2845617A1 (enExample)
SG (2) SG11201400067TA (enExample)
WO (1) WO2013024362A2 (enExample)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155590A (en) 1962-08-02 1964-11-03 Ncr Co Encapsulation process and its product
US3488418A (en) 1965-11-18 1970-01-06 Sterling Drug Inc Sustained relief analgesic composition
US3391416A (en) 1966-07-14 1968-07-09 Wollard Aircraft Service Equip Conveyance loader system
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JP4181232B2 (ja) 1997-07-18 2008-11-12 帝國製薬株式会社 ジクロフェナクナトリウム含有油性外用貼付製剤
US6193996B1 (en) 1998-04-02 2001-02-27 3M Innovative Properties Company Device for the transdermal delivery of diclofenac
US6410041B1 (en) 1998-04-28 2002-06-25 Trustees Of Tufts College Culturing cells in presence of amphipathic weak bases and/or cations and multiple drug resistance inhibitor containing reserpine
CA2345641A1 (en) 1998-09-28 2000-04-06 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
US20050171021A1 (en) * 1998-11-12 2005-08-04 Cormier Michel J. Buffered drug formulations for transdermal
US6309380B1 (en) 1999-01-27 2001-10-30 Marian L. Larson Drug delivery via conformal film
GB9917165D0 (en) * 1999-07-22 1999-09-22 Knoll Ag Polypeptides polynuclcotides and uses thereof
US6273831B1 (en) * 1999-09-03 2001-08-14 Callaway Golf Company Golf club head with a polymer insert
WO2005052593A1 (en) 2003-10-29 2005-06-09 The University Of Leicester Detection
AU2005207886A1 (en) * 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel brain natriuretic peptide variants and methods of use thereof
EP2089722B1 (en) * 2006-09-07 2017-11-08 Otago Innovation Limited Biomarker for early detection of acute cardiac disorders

Also Published As

Publication number Publication date
JP2014524435A (ja) 2014-09-22
CA2845617A1 (en) 2013-02-21
CN103889438A (zh) 2014-06-25
US9783574B2 (en) 2017-10-10
EP2744506A2 (en) 2014-06-25
US20180148475A1 (en) 2018-05-31
EP2744506B1 (en) 2019-10-09
SG10201601086WA (en) 2016-03-30
CN103889438B (zh) 2016-08-24
US20130072431A1 (en) 2013-03-21
AU2012296266B2 (en) 2017-08-31
WO2013024362A2 (en) 2013-02-21
WO2013024362A3 (en) 2013-07-25
EP2744506A4 (en) 2015-06-03
SG11201400067TA (en) 2014-04-28
AU2012296266A1 (en) 2014-03-13
NZ621790A (en) 2017-09-29

Similar Documents

Publication Publication Date Title
RU2332229C2 (ru) Способ введения молекул glp-1
US5641744A (en) Treatment of diabetes mellitus
US11541028B2 (en) Peptide pharmaceuticals for treatment of NASH and other disorders
US5175145A (en) Treatment of diabetes mellitus with amylin agonists
EP2552470B1 (en) Peptides for promoting angiogenesis and an use thereof
CN103764159A (zh) 芳香族阳离子肽及其用途
CN102791280A (zh) 用于预防或治疗血管阻塞损伤的方法
JP7606966B2 (ja) ミトコンドリア病を標的とするアナログ
CN102711801A (zh) 用顶压素样肽治疗心力衰竭的方法
JP2022504596A (ja) ヒトアミリンアナログペプチド及び使用方法
AU2021399904B2 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
US9107870B2 (en) Angiotensin peptides in treating marfan syndrome and related disorders
US20240024425A1 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
JP2022511939A (ja) ミトコンドリア標的化ペプチド
US20230405088A1 (en) Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
WO2013192238A2 (en) Compositions and methods for treatment of diabetes
CN119454605B (zh) 一种实现多肽口服吸收的组合物
JP2014524435A (ja) 心血管治療法
WO2017192620A2 (en) Novel peptides and peptidomimetics
NZ621790B2 (en) Cardiovascular therapeutics
WO2025123051A1 (en) Non-naturally occurring melanocortin analogs and uses thereof for modulating weight gain
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170823

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170929

R150 Certificate of patent or registration of utility model

Ref document number: 6222779

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees